Bv8 (prokineticin 2) expressed by Gr1 þ
Introduction
Because tumor growth is strictly dependent on angiogenesis, the identification of tumor angiogenic factors and the cells that produce them is a major goal. Although VEGF was identified as one of the most potent angiogenic factors, many tumors become resistant to anti-VEGF therapy (1) . Myeloid cells that express surface markers Gr1 and CD11b are the main regulators of tumor refractoriness to anti-VEGF treatment in immunocompetent rodent tumor models (1) . Gr1 þ CD11b þ cells promote resistance to anti-VEGF therapy by expression of matrix metalloproteinase 9 (MMP9) or by direct incorporation into the endothelium (2) . Among the signaling pathways studied, Stat3 is a key signal transducer in Gr1 þ CD11b þ cell-mediated tumor angiogenesis (3) . More recently, the proangiogenic factor Bv8 or prokineticin2 has been shown to be specifically upregulated by granulocyte colony-stimulating factor (G-CSF) in anti-VEGF refractory tumors (4, 5) . The proangiogenic activities of Gr1 þ CD11b þ cells depend on G-CSF, starting from the bone marrow and continuing with their migration to the tumor, promoting both angiogenesis and tumor invasion (6) (7) (8) . Thus, regulation of Bv8 production by Gr1 þ CD11b þ myeloid cells is a new target for the inhibition of tumor growth and angiogenesis (5, 9, 10) . Bv8 was first characterized as a protein of 77 amino acids from Bombina variegata skin secretions and later shown to have 70% similarity to endocrine gland-derived VEGF (EG-VEGF) or prokineticins-1 and -2 (8, 11) . Both have a 5-disulfidebridge motif and associate with G-protein-coupled receptors, EG-VEGFR1 (or PKR1) and EG-VEGFR2 (or PKR2; refs. 8, 11) . Bv8 promotes proliferation of endothelial cells, hematopoiesis, and hematopoietic cell migration (8, 12) . Blocking Bv8 or its upregulator G-CSF in tumor-bearing mice with either anti-Bv8-or anti-G-CSF-neutralizing antibodies inhibits tumor angiogenesis and tumor growth (5, 7) . However, the mechanism of G-CSF regulation of Bv8 in Gr1 þ
CD11b
þ cells has not been studied. Thus, identification of negative regulators of these cells presents an opportunity to control their protumorigenic activities.
We have recently identified carcinoembryonic antigenrelated cell adhesion molecule-1 (CEACAM1) as a critical regulator of granulopoiesis, which depends on G-CSF-R and Stat3 signaling (13) . CEACAM1, highly expressed on granulocytes in both man and rodents, has multiple splice forms including a long cytoplasmic domain isoform that encodes 2 ITIMs (14) . Phosphorylation of its ITIMs recruits the inhibitory phosphatase SHP-1, which in turn, dephosphorylates G-CSF receptor (G-CSFR), thus inhibiting the progranulocytic activity of G-CSFR (13) . Although CEACAM1 is recognized as a tumor suppressor gene because of its downregulation in solid tumors including colon (15) , prostate (16) , and breast (17) , the mechanism is not well-understood. In fact, in some tumors such as melanoma, upregulation of CEACAM1 has been observed, throwing doubt on its role as a general tumor suppressor (18, 19) . Although tumor growth in Ceacam1 À/À mice is accelerated (20, 21) , the role of CEACAM1 expression in the tumor is controversial. Alternatively, the function of CEACAM1 in myeloid cells and lymphocytes may play a larger role than the expression of CEACAM1 itself in tumors. In this respect, we are interested in connecting the very high expression of CEACAM1 in Gr1 þ CD11b þ cells and its role in G-CSF signaling to its newly assigned role in angiogenesis. For example, Ergun and colleagues have shown that CEACAM1 plays a significant role in angiogenesis in endothelial cells (22) (23) (24) (25) and we have shown that CEACAM1 is required for vasculogenesis in embryonic stem cells (26) . Despite these connections, the mechanism of the function of CEACAM1 in myeloid cell-mediated tumor angiogenesis is unknown.
In this study, we show that genetic loss of CEACAM1 leads to increased Bv8 expression in Gr1 
þ myeloid cell infiltration into the blood and spleen, which in turn reduced tumor angiogenesis and tumor growth in WT mice. These results underscore the inhibitory role of CEACAM1 in myeloid cell-mediated tumor angiogenesis, indicating that CEACAM1 is a promising target for tumor immunotherapy.
Materials and Methods
Antibodies Anti-Bv8 antibodies 2B9 and 3F1 were from Genentech, Inc., anti-G-CSF MAB414 and isotype control from R&D Systems, anti-CEACAM1 CC1 from Kathryn Holmes (University of Colorado, Denver, CO), and anti-VEGF-A (2G11-2A05) and antiGr1 (RB6-8C5) from Biolegend. The isotype control for the antiBv8 and anti-CEACAM1 treatments was murine anti-human CD33 (IgG1 produced in-house at City of Hope, Duarte, CA).
Tumor cell lines and animals
B16F10 and MC38 cells were from American Type Culture Collection and maintained in Dulbecco's Modified Eagles' Media (DMEM) supplemented with 10% FBS. Ceacam1 À/À mice were provided by Dr. Beauchemin (McGill University, Montreal, QC, Canada). B16 tumor cells (10 5 ) in 100 mL PBS were injected s.c. into 8-to 12-week-old WT or transgenic mice, and tumor sizes measured every 2 to 3 days.
Isolation of tumor-infiltrating immune cells
Tumors were cut into 1 to 2 mm 3 and digested for 30 minutes at 37 C by collagenase D/DNase I (Roche) in DMEM. Cell suspensions were filtered through a 70-mm cell strainer, and dead cells were removed by centrifugation at 600 Â g over a Histopaque gradient (Sigma-Aldrich).
Bone marrow reconstitution assay
Bone marrow from C57BL/6 and Ceacam1 À/À mice (donors) was transferred into Ceacam1 À/À and C57BL/6 lethally irradiated recipients. Retroviral vectors were constructed as previously described (13 ) in 600 mL of growth factor-reduced Matrigel (BD Biosciences) were injected into WT or Ceacam1 À/À mice. Matrigel plugs were dissected 6 days later and analyzed for hemoglobin content by colorimetry using the Drabkin reagent (Sigma-Aldrich) or stained for CD31 or Gr1. 
Co-injection of tumor cells with Gr1

CD11b
þ cells were sorted and injected into the tumor site.
Immunohistochemistry and immunofluorescence
For immunohistochemical analysis, the primary antibody was rat anti-mouse CD31 1/25 (BD Pharmingen 550274) and the secondary rabbit anti-rat secondary antibody from Vector Labs. For immunofluoresent staining, 5-mm sections of flashfrozen tumor specimens were fixed in acetone, permeabilized with methanol, incubated with rat anti-mouse Gr1 þ or rat antimouse CD31 in PBS supplemented with 10% goat serum and 2.5% mouse serum, and detected with goat anti-rat-conjugated Alexa Fluor 546 or 488 (Invitrogen). ) AE G-CSF treatment (50 ng/mL, 6-8 hours) were lysed using RIPA buffer (Sigma) supplemented with 4 mmol/L Na 3 VO 4 , 50 mmol/L NaF, and 1 mmol/L phenylmethylsulfonylfluoride and immunoblotted with antiBv8. Tumors from C57BL/6 and Ceacam1 À/À mice were homogenized, filtered (70-mm strainer), centrifuged, and cultured (2 Â 10 6 ) in DMEM supplemented with 10% FBS overnight. Supernatants were analyzed for G-CSF and VEGF using ELISA kits (R&D Systems). Two-tailed P values were calculated by the unpaired t test using Prism software (GraphPad Software, Inc.).
Results
Enhanced tumor growth and angiogenesis in CEACAM1
À/À mice Although CEACAM1 is recognized as a tumor suppressor gene because of its downregulation in many solid tumors including colon (15, 27, 28) , prostate (16) , and breast (17) , the opposite is found in melanoma (18, 29) and lung cancer (30, 31) . Notably, few studies focused on the role of CEACAM1 expression in the tumor microenvironment, including immune cells that promote tumor growth and angiogenesis. To approach this problem, we selected a tumor model in immune competent mice that had either WT expression or no expression of CEACAM1. C57BL/6 or Ceacam1 À/À mice were challenged with the syngeneic melanoma cell line B16F10. Tumor growth was enhanced significantly (about 2-fold) in Ceacam1
À/À compared with WT mice (Fig. 1A) . Because tumor growth is dependent on new blood vessel formation, we determined whether the enhanced tumor growth in Ceacam1 À/À mice was associated with increased tumor angiogenesis. Indeed, tumor blood vessel density was about 2-fold higher in Ceacam1 Enhanced tumor growth and angiogenesis is dependent on bone marrow-derived cells but independent of T and B cells Bone marrow-derived myeloid cells, such as macrophages, granulocytes, and dendritic cells, play a critical role in mediating tumor growth and angiogenesis (32) . To determine whether bone marrow-derived cells are responsible for the enhanced tumor growth and angiogenesis in Ceacam1
À/À mice, we generated bone marrow chimeras. Ceacam1
À/À and WT mice were lethally irradiated and reconstituted with bone marrow from either WT or Ceacam1 À/À mice, respectively.
After 8 weeks, B16 melanoma cells were injected s.c. in the bone marrow-reconstituted mice. Tumor growth in WT recipients with Ceacam1 À/À bone marrow was enhanced compared with that in Ceacam1 À/À recipients with WT bone marrow ( Fig. 2A ).
Tumor growth was dependent on the donor bone marrow rather than the recipient. Consistently, immunohistochemical analysis revealed increased numbers of blood vessels in WT recipients with Ceacam1 À/À bone marrow compared with 
Inhibitory regulation of tumor growth by Ceacam1 is dependent on its ITIMs
The ITIM domains on the long cytoplasmic domain isoform of CEACAM1 carried out an inhibitory role in the immune system by recruiting SHP-1/2 phosphatases, which attenuate signaling pathways in lymphocytes (14, 33) . When the tyrosines in the ITIMs were mutated to Phe or Ala, their inhibitory activity was abolished (33) . Previously, we have shown that the ITIMs in the long cytoplasmic domain isoform of CEACAM1 in granulocytes inhibit granulopoiesis by recruiting SHP-1 and inhibiting activated G-CSFR signaling (13) . Because our data suggest that CEACAM1 is an inhibitory mediator for tumor growth and angiogenesis in the B16 melanoma tumor model, it was important to show that CEACAM1 inhibits tumor growth through its ITIM domains. Therefore, we reconstituted WT or Tyr-mutated long cytoplasmic isoforms of CEACAM1 into Ceacam1 À/À mouse bone marrow. As a control, we also reconstituted Ceacam1 À/À mouse bone marrow with the short cytoplasmic domain isoform that lacks ITIMs. We found that only the long cytoplasmic domain isoform of CEACAM1 was able to restore tumor growth to levels compared with WT mice (Supplementary Fig. S2A ), whereas the short cytoplasmic domain isoform of CEACAM1 did not play a role in tumor growth inhibition ( Supplementary Fig. S2B ). Furthermore, mutation of the ITIMs on the long cytoplasmic domain isoform of CEACAM1 failed to suppress tumor growth ( Supplementary  Fig. S2A ). Thus, bone marrow reconstitution analysis indicates that the ITIMs of the long cytoplasmic domain isoform of CEACAM1 are responsible for its role in tumor growth inhibition. Fig. 3A and B) . Flow cytometric analysis of dissociated tumor tissue also confirmed that the population of Gr1 þ CD11b þ myeloid cells in tumor is higher in Ceacam1 À/À than in WT mice ( Fig. 3C and Supplementary Fig.   S3 ). Furthermore, the percentage of Gr1 þ CD11b þ myeloid cells is significantly increased in spleen, peripheral blood, and bone marrow of Ceacam1 À/À mice, indicating that production and the migration of these cells into the periphery are increased (Fig. 3C) . Flow cytometric analysis also showed that infiltration of Gr1 (Fig. 3D) . These data also suggest that the Ceacam1 À/À Gr1 þ CD11b þ cells have an enhanced ability to migrate into peripheral tissues and might be responsible for enhanced tumor growth and angiogenesis. Consistently, the population of Gr1 þ CD11b þ cells in tumor, spleen, blood, and bone marrow is higher in Ceacam1
Enhanced infiltration of Gr1
mice than in Rag1 À/À mice, indicating that the enhanced infiltration of these cells in Ceacam1 À/À mice is independent of T and B cells (Fig. 3D) . A similar increase in infiltrating Gr1 þ cells was seen in Matrigel plugs in Ceacam1 À/À mice (Fig. 3E ).
When tumors were stained for NK cells, the percentage of activated NK cells was lower in the Ceacam1 À/À (2.7%) than in WT mice (3.2%; data not shown). (2, 5, 32) . Bv8 expression in the bone marrow of tumor-bearing mice is positively regulated by G-CSF (5), the major cytokine responsible for granulopoiesis. Because we found that CEACAM1 is a negative regulator of the G-CSFR signaling pathway in myeloid progenitor cells (13), we thought it likely that CEACAM1 would regulate G-CSF-mediated Bv8 expression. Previously, we showed that after G-CSF binds to G-CSFR, CEACAM1 associates with G-CSFR recruiting SHP-1, which in turn, dephosphorylates activated G-CSFR and Stat3 signaling, resulting in the attenuation of granulopoiesis (13) . Given these findings, we determined whether CEACAM1 negatively regulates G-CSF-driven Bv8 production in Gr1 þ CD11b þ myeloid cells, thus accounting for the mechanism of increased tumor growth and angiogenesis in Ceacam1 À/À mice. First, we found that G-CSF levels were elevated in tumors from Ceacam1 À/À mice (Fig. 5A) . Second, we found that VEGF levels were similar in tumors from WT or Ceacam1 À/À mice (Fig. 5A ), indicating that VEGF does not play an important role in mediating enhanced tumor angiogenesis in Ceacam1 À/À mice. Gr1 þ CD11b þ myeloid cells isolated from Ceacam1 À/À spleens or tumors showed higher Bv8 mRNA transcript levels compared with WT controls (Fig. 5B) . However, there was no significant change of VEGF mRNA transcripts in WT or Ceacam1
Gr1
from tumor or spleen (Fig. 5C ). Because the expression of Bv8 is regulated by G-CSF, we determined whether the G-CSF-Bv8 pathway in Ceacam1 À/À myeloid cells was more active than in WT controls. We enriched bone marrow Gr1 
Tumor Spleen
Tumor Spleen (Fig. 5D) . Also WT Gr1 À CD11b À cells make negligible amounts of Bv8 mRNA in response to G-CSF (Fig. 5D ). The Bv8 mRNA transcript level is about 7-fold higher in Ceacam1
þ myeloid cells in response to the same dose of G-CSF (Fig. 5D) . Western blot analysis confirmed that the expression of Bv8 protein in Ceacam1 À/À Gr1 þ CD11b þ myeloid cells was higher than in WT controls with G-CSF treatment (Fig. 5E) . Importantly, in the absence of G-CSF, there was no significant difference in Bv8 protein expression in Ceacam1 À/À compared with WT Gr1 þ CD11b þ myeloid cells (Fig. 5E ). As expected,
Gr1
À CD11b À cells make negligible amounts of Bv8 protein (data not shown).
Anti-G-CSF, anti-Bv8, or anti-VEGF treatments delayed tumor growth and angiogenesis in Ceacam1 À/À mice Tumor-associated Gr1 þ CD11b þ cells were increased in Ceacam1 À/À mice with concomitant expression of proangiogenic factor Bv8 in Gr1
G-CSF, the major upregulator of Bv8, was also increased in the tumors from Ceacam1 À/À mice. To test whether elevated Bv8 and G-CSF were responsible for the enhanced tumor growth and angiogenesis in Ceacam1 À/À mice, we treated Ceacam1 À/À tumor-bearing mice with anti-Bv8 or anti-G-CSF antibody. We found that anti-Bv8 antibody treatment significantly reduced the tumor growth in Ceacam1 À/À mice to the level in controls (Fig. 6A) . We also found that anti-Bv8 antibody treatment remarkably reduced both tumor angiogenesis and tumor-associated Gr1 þ infiltrates in Ceacam1 À/À mice ( Fig.   6B-D) . Thus, our data indicate that Bv8 plays a critical role in mediating the increased tumor growth and angiogenesis in Ceacam1 À/À mice in B16F10 melanoma model.
Similarly, anti-G-CSF antibody treatment significantly reduced tumor growth and the infiltration of Gr1 þ CD11b þ myeloid cells in tumor-bearing Ceacam1 À/À mice, but not in WT mice (Supplementary Fig. S4A ). The number of blood vessels in tumors from Ceacam1 À/À mice decreased with anti-G-CSF treatment, but not in WT mice ( Supplementary  Fig. S4B and S4C ). Anti-G-CSF treatment reduced the population of Gr1 þ CD11b þ in the bone marrow of Ceacam1 À/À and WT mice, whereas the number of Gr1 þ CD11b þ cells in the spleen was not significantly reduced in WT compared with Ceacam1 À/À mice ( Supplementary Fig. S4D ), which may explain why tumor growth was not reduced in response to anti-G-CSF treatment in WT mice. These results indicate that the increased G-CSF-Bv8 signaling in Ceacam1 À/À mice plays a major role in mediating the increased tumor growth in Ceacam1 À/À mice, indicating that CEACAM1 is a negative regulator in this pathway. Although VEGF mRNA levels are similar in B16 tumors from WT and Ceacam1 À/À mice (Fig. 5C ), the production of VEGF is likely to play some role in tumor growth (i.e., tumor growth is reduced not eliminated in anti-Bv8-treated mice). Indeed, anti-VEGF treatment of Ceacam1 À/À mice bearing B16 tumors significantly reduced tumor size (Fig. 7A) as well as tumor vasculature (Fig. 7B ) and the numbers of infiltrating Gr1 þ cells (Fig. 7C) . However, because treatment of tumor-bearing Ceacam1 À/À mice with a combination of anti-Bv8 and anti-VEGF antibodies had no additive effects (Fig. 7A) , it is likely that they operate independently of each other in this animal model. 
Anti-CEACAM1 treatment delayed tumor growth and angiogenesis in WT mice
To test whether CEACAM1 was a potential therapeutic target for cancer treatment, we treated WT tumor-bearing mice with an anti-CEACAM1 antibody. Indeed, we found that anti-CEACAM1 antibody treatment reduced both tumor growth and angiogenesis ( Supplementary Fig. S5A-S5C ). Because CEACAM1 is predominantly expressed on Gr1 
Enhanced MC38 colon tumor growth in Ceacam1
À/À mice Because we observed accelerated B16 melanoma tumor growth in Ceacam1 À/À mice and CEACAM1 expression has been associated with a poor prognosis in human melanoma (18) , it was important to determine whether the role of CEACAM1 in myeloid cells was specific to the melanoma tumor model. Therefore, we tested whether tumor growth, angiogenesis, and the phenotype of infiltrating myeloid cells were similar in a second syngeneic tumor model. The MC38 colon tumor was chosen because CEACAM1 is a tumor suppressor in colon cancer (15, 27) . MC38 tumor growth in Ceacam1 À/À mice was significantly more aggressive than in S7D -S7F). Therefore, lack of expression of CEACAM1 in Ceacam1 À/À host myeloid cells enhances tumor growth in a second model system that is usually associated with a tumor suppressor role for CEACAM1. We conclude that CEACAM1-mediated inhibition of myeloid cell infiltration and tumor angiogenesis is not specific to the B16 melanoma tumor model and may be a general feature of the regulated role of myeloid cells in tumor development.
Discussion
Although the cell-cell adhesion molecule CEACAM1 is downregulated in a number of cancers, including prostate (16), breast (17) , and colon (27, 28) , the precise mechanism of its tumor suppressive activity is unclear. In fact, there is evidence in several cancers such as melanoma (19) and lung (31) that CEACAM1 expression correlates with a poor prognosis. Although most research has focused on the role of Ceacam1 in cancer cells, the role of Ceacam1 in immune cell-mediated tumorigenesis and tumor angiogenesis is less studied. For example, bone marrow-derived lymphocytes and myeloid cells are known to play critical roles in tumor growth and angiogenesis. In support of this idea, we show in the B16 melanoma tumor model that an enhanced tumor growth and angiogenesis in Ceacam1 À/À mice are mediated by bone marrow cells using a reverse bone marrow transplantation treatments have been shown to reduce tumor growth and angiogenesis (5, 7). Because our group previously found that CEACAM1 is a negative regulator of the G-CSFR-Stat3 pathway in myeloid progenitor cells (13) and G-CSF mediates Bv8 production, we hypothesized that CEACAM1 also regulates this pathway. In the case of myeloid progenitors, G-CSF recruits CEACAM1 to G-CSFR where both G-CSFR and CEA-CAM1 are phosphorylated. The phosphorylation of CEACAM1 on its ITIMs recruits the inhibitory phosphatase SHP-1, which in turn, dephosphorylates G-CSFR and its downstream signaling mediator Stat3 (13) . In agreement with the role of CEA-CAM1 in negatively regulating the G-CSFR-Stat3 pathway in myeloid cells, this study shows that CEACAM1 is also a negative regulator of the G-CSF-Bv8 axis in Gr1
Proof that this role is provided by the ITIMs on CEACAM1 was shown by bone marrow reconstitution of WT long isoform, but not ITIM mutants or the short form isoform of CEACAM1 lacking ITIMs can reduce tumor growth and angiogenesis to WT levels. Thus, the ITIM domains on the long isoform of CEACAM1 are responsible for its inhibitory activity. These results not only emphasize the important role of G-CSF in stimulating Bv8-mediated tumor angiogenesis but also the requirement for its negative regulation by CEACAM1. In addition, this role of CEACAM1 may apply to other cells that express CEACAM1 and use the G-CSF pathway. We conclude that tumor angiogenesis, like angiogenesis in general, must be tightly controlled by both positive and negative regulators. Distinct functions of CEACAM1 in angiogenesis have been explored in different cell types and in different models. In endothelial cells, CEACAM1 activates angiogenesis by reorganizing cytoskeleton and integrin signaling (24, 37) . Deletion of CEACAM1 in primary murine lung endothelial cells induces defective vascular permeability (25) , perhaps indicating a role for CEACAM1 in blood vessel stability. Downregulation of CEACAM1 in epithelial cells in prostate intraepithelial neoplasia was followed by enhanced vascularization of prostate tumors, a result attributed to an unknown secreted factor produced by CEACAM1-positive prostate epithelial cells that inhibits angiogenesis (38) . In our own study, we found that CEACAM1 is required for vasculogenesis in embryonic stem cells (26) . Vascular sprouting was inhibited by either anti-CEACAM1 or anti-PECAM1 antibodies, emphasizing that both receptors are required for neovascularization. Anti-CEACAM1 antibodies were able to inhibit tumor growth and angiogenesis in our B16 melanoma model by reducing the Gr1 þ CD11b þ cells.
About the effect of CEACAM1 in immune cell-mediated angiogenesis, it was reported that CEACAM1 is required for Ly6C þ CD11b þ monocyte-mediated angiogenesis in inflammation in a model of cutaneous leishmaniasis (23) . In contrast, in our melanoma tumor model, we found that Gr1 þ CD11b þ myeloid cells from Ceacam1 À/À mice have an enhanced ability to promote tumor angiogenesis, indicating that CEACAM1 negatively regulates tumor angiogenesis. Although these studies may suggest opposing roles of CEACAM1 in wound healing or inflammation-associated angiogenesis versus tumor angiogenesis, it can be argued that they are all consistent with a role for CEACAM1 in controlling the degree of angiogenesis by regulation of G-CSFR-Stat3 signaling. Even in our tumor model, CEACAM1-positive myeloid cells are able to sustain tumor growth. It is only in the absence of CEACAM1 that tumor growth is enhanced by the myeloid cells. Because CEACAM1 is able to prevent unrestrained tumor growth, it may play a similar role in angiogenesis in general. To sort out these apparent discrepancies, a complete analysis of the signaling pathways used is necessary, especially in VEGF-independent angiogenesis. In summary, our findings show the significance of the inhibitory regulation of Gr1 þ CD11b þ myeloid cell-mediated tumor growth and angiogenesis by CEACAM1 through the G-CSF-Bv8 axis. The fact that antibody-mediated therapy against Bv8 and G-CSF, as well as CEACAM1, reduces tumor growth underscores the identification of CEACAM1 as a novel therapeutic potential target for tumor angiogenesis.
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